{
    "clinical_study": {
        "@rank": "60249", 
        "arm_group": [
            {
                "arm_group_label": "Tecnis Multifocal Intraocular lens #1", 
                "arm_group_type": "Experimental", 
                "description": "A low diopter add multifocal intraocular lens"
            }, 
            {
                "arm_group_label": "Tecnis Multifocal Intraocular Lens #2", 
                "arm_group_type": "Experimental", 
                "description": "A low diopter add multifocal intraocular lens"
            }, 
            {
                "arm_group_label": "Monofocal Intraocular Lens", 
                "arm_group_type": "Active Comparator", 
                "description": "Commercially available monofocal intraocular lens (IOL)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this clinical trial is to evaluate the safety and effectiveness of the TECNIS\n      Multifocal 1-Piece Intraocular Lens (IOLs), Models ZKB00 and ZLB00 which will each provide\n      statistically better distance-corrected near visual acuity compared to the monofocal control\n      lens. Complication and adverse event rates associated with each Multifocal IOL will be\n      within the ISO SPE rate for posterior chamber IOLs."
        }, 
        "brief_title": "Clinical Investigation of Expanded Designs of a Multifocal IOL", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Cataract", 
        "condition_browse": {
            "mesh_term": "Cataract"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Minimum 18 years of age\n\n          -  Bilateral cataracts for which phacoemulsification extraction and posterior IOL\n             implantation have been planned for both eyes\n\n          -  Preoperative best-corrected distance visual acuity (BCDVA) of 20/40 or worse\n             (Snellen) with or without a glare source\n\n          -  Potential for postoperative best-corrected visual acuity of 20/25 or better\n\n          -  Preoperative corneal astigmatism of 1.0 D or less with normal corneal topography and\n             no irregular corneal astigmatism\n\n          -  Clear intraocular media, other than cataract\n\n          -  Availability, willingness and sufficient cognitive awareness to comply with\n             examination procedures\n\n          -  Signed informed consent and HIPAA authorization or equivalent documentation necessary\n             to comply with applicable privacy laws pertaining to medical treatment in the\n             governing countries\n\n          -  Ability to understand and respond to a questionnaire verbally administered in English\n\n        Exclusion Criteria:\n\n          -  Requiring an intraocular lens power outside the available range of +16.0 to +28.0 D\n\n          -  Pupil abnormalities (non-reactive, fixed pupils, or abnormally shaped pupils)\n\n          -  Recent ocular trauma or ocular surgery that is not resolved/stable or may affect\n             visual outcomes\n\n          -  Prior refractive (LASIK, LASEK, RK, PRK, etc.) or intraocular surgery\n\n          -  Corneal abnormalities such as stromal, epithelial or endothelial dystrophies that are\n             predicted to cause visual acuity losses to a level of 20/30 or worse during the study\n\n          -  Inability to achieve keratometric stability for contact lens wearers\n\n          -  Subjects with diagnosed degenerative visual disorders (e.g., macular degeneration or\n             other retinal disorders) that are predicted to cause visual acuity losses to a level\n             of 20/30 or worse during the study\n\n          -  Subjects with conditions associated with increased risk of zonular rupture, including\n             capsular or zonular abnormalities that may lead to IOL decentration, including\n             pseudoexfoliation, trauma, or posterior capsule defects\n\n          -  Use of systemic or ocular medications that may affect vision\n\n          -  Prior, current, or anticipated use during the course of the 12-month study of\n             tamsulosin or silodosin (e.g., Flomax\u00ae, Flomaxtra\u00ae, Rapaflo\u00ae) likely, in the opinion\n             of the investigator, to cause poor dilation or lack of adequate iris structure to\n             perform standard cataract surgery\n\n          -  Inability to focus, fixate or maintain binocular vision for prolonged periods of time\n             (e.g., due to strabismus, nystagmus, etc.)\n\n          -  Poorly-controlled diabetes\n\n          -  Acute, chronic, or uncontrolled systemic or ocular disease or illness that, in the\n             opinion of the investigator, would increase the operative risk or confound the\n             outcomes of the study (e.g., immunocompromised, connective tissue disease, suspected\n             glaucoma, glaucomatous changes in the fundus or visual field, ocular inflammation,\n             etc.).  Note: ocular hypertension without glaucomatous changes is acceptable.\n\n          -  Known ocular disease or pathology that may affect visual acuity or that may be\n             expected to require retinal laser treatment or other surgical intervention during the\n             course of the study (macular degeneration, cystoid macular edema, diabetic\n             retinopathy, etc.)\n\n          -  Patient is pregnant, plans to become pregnant, is lactating or has another condition\n             associated with the fluctuation of hormones that could lead to refractive changes\n\n          -  Concurrent participation or participation within 30 days prior to preoperative visit\n             in any other clinical trial\n\n          -  Desire for monovision correction"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01714635", 
            "org_study_id": "DIOL-106-ZMLA"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Tecnis Multifocal Intraocular lens #1", 
                    "Tecnis Multifocal Intraocular Lens #2"
                ], 
                "intervention_name": "Tecnis Multifocal Intraocular Lens", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Monofocal Intraocular Lens", 
                "intervention_name": "Monofocal Intraocular Lens", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "cataract", 
            "IOL", 
            "intraocular lens"
        ], 
        "lastchanged_date": "December 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Indianapolis", 
                    "country": "United States", 
                    "state": "Indiana", 
                    "zip": "46256"
                }, 
                "name": "Eye Surgeons of Indiana"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Clinical Investigation of Expanded Designs of the Tecnis\u00ae Multifocal 1-Piece IOL", 
        "other_outcome": {
            "description": "Postoperative complication and adverse event rates vs. ISO SPE rates", 
            "measure": "Adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "overall_official": {
            "affiliation": "Abbott Medical Optics", 
            "last_name": "Kendra Hileman, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Mean (LogMAR) monocular distance-corrected near visual acuity under photopic conditions at 40 cm at six months postoperative", 
            "measure": "Distance-corrected near visual acuity (VA) under photopic conditions for both higher-add and lower add lens models", 
            "safety_issue": "No", 
            "time_frame": "six months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01714635"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Mean binocular, best-corrected depth-of-focus (defined as the maximum diopters of defocus at which 20/40 or better visual acuity is achieved) at six months postoperative for both higher-add lens model and lower-add lens model", 
                "measure": "Mean binocular best-corrected depth-of-focus", 
                "safety_issue": "No", 
                "time_frame": "six months"
            }, 
            {
                "description": "Proportion of subjects achieving spectacle independence at six months for both the higher-add and lower-add lens models.", 
                "measure": "Spectacle independence", 
                "safety_issue": "No", 
                "time_frame": "six months"
            }, 
            {
                "description": "Proportion of subjects achieving combined best-corrected distance visual acuity (binocular BCDVA 20/25 or better) and distance-corrected near visual acuity (binocular DCNVA 20/32 or better) at six months postoperative for both higher-add and lower-add lens models", 
                "measure": "Combined best-corrected distance visual acuity (BCDVA) and distance-corrected near visual acuity (DCNVA)", 
                "safety_issue": "No", 
                "time_frame": "six months"
            }
        ], 
        "source": "Abbott Medical Optics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abbott Medical Optics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}